Budesonide
( DrugBank: Budesonide / KEGG DRUG: Budesonide )
7 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 66 | IgA nephropathy | 33 |
| 93 | Primary biliary cholangitis | 15 |
| 94 | Primary sclerosing cholangitis | 1 |
| 95 | Autoimmune hepatitis | 3 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 96 | Crohn disease | 29 |
| 97 | Ulcerative colitis | 57 |
| 98 | Eosinophilic gastro-intestinal disorder | 46 |
66. IgA nephropathy
Clinical trials : 349 / Drugs : 251 - (DrugBank : 75) / Drug target genes : 43 - Drug target pathways : 152
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
93. Primary biliary cholangitis
Clinical trials : 352 / Drugs : 206 - (DrugBank : 55) / Drug target genes : 40 - Drug target pathways : 119
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
94. Primary sclerosing cholangitis
Clinical trials : 177 / Drugs : 120 - (DrugBank : 48) / Drug target genes : 25 - Drug target pathways : 148
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
95. Autoimmune hepatitis
Clinical trials : 58 / Drugs : 56 - (DrugBank : 27) / Drug target genes : 23 - Drug target pathways : 114
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
96. Crohn disease
Clinical trials : 2,737 / Drugs : 1,197 - (DrugBank : 240) / Drug target genes : 182 - Drug target pathways : 221
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
97. Ulcerative colitis
Clinical trials : 3,305 / Drugs : 1,646 - (DrugBank : 318) / Drug target genes : 165 - Drug target pathways : 220
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
98. Eosinophilic gastro-intestinal disorder
Clinical trials : 214 / Drugs : 171 - (DrugBank : 46) / Drug target genes : 48 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|